Last month, AI intelligence company AppliedXL announced a partnership with Kalshi to launch a biotech prediction markets pilot, covering clinical trial outcomes and FDA regulatory decisions on named drug candidates. Initial contracts include questions on AR1001’s POLARIS-AD Phase 3 trial in early Alzheimer’s disease and FDA approval of anito-cel, the CAR-T therapy developed by Gilead and Arcellx for relapsed/refractory multiple myeloma.
The Launch of Kalshi’s Biotech Prediction Markets Pilot
The program’s pilot pairs Kalshi’s exchange infrastructure with AppliedXL’s resolution technology, which collects and structures public evidence before trading begins and ties each contract to a named official document including ClinicalTrials.gov primary endpoints, FDA approval letters, or advisory committee vote records. That approach shifts the interpretive ambiguity that has historically plagued event-driven biotech trading; every market resolves against a specific public filing rather than a judgment call by a third party.
Kalshi restricted the pilot to late-stage trials or markets listed after enrollment closes, a deliberate choice to address the most obvious regulatory concern: that open prediction markets could distort recruitment decisions or tip the hand of investigators who already know interim results.
Kalshi requires employment verification for all traders in these markets and bars participation by people with material nonpublic information, patients enrolled in trials, or employees of sponsor companies such as Gilead and Arcellx. Kalshi has also stated it will not open markets in any configuration that could affect trial recruitment.
AppliedXL’s role extends beyond picking the resolution document. The firm defines interpretation criteria before a contract goes live, eliminating post-hoc disputes about whether a trial met its primary endpoint or whether an FDA response letter constitutes a refusal. That pre-specification of criteria is borrowed from the clinical trial playbook itself and gives institutional participants a clean framework for pricing probability.
The two companies published a joint whitepaper titled “Biopharma’s Public Probability: The State and Future of Prediction Markets in Drug Development” alongside the launch, signaling that this is positioned as a research-grade initiative rather than a speculative product. As of August 2026, the program remains a pilot, with both companies’ studying performance before committing to a broader expansion.
About AppliedXL
AppliedXL is an AI intelligence company providing real-time monitoring and resolution technology to information providers, including Bloomberg and Dow Jones, as well as pharmaceutical companies and hedge funds. Founded by the former R&D chief of The Wall Street Journal, the company operates as an AI and computational journalism lab focused on turning fragmented public records into structured, verifiable intelligence.
AppliedXL has become the independent resolution-analysis provider for Kalshi’s new biotech and pharmaceutical prediction markets discussed above, which covers clinical trial readouts and regulatory decisions. The partnership applies AppliedXL’s technology to resolving markets tied to specific clinical and regulatory outcomes. AppliedXL monitors the relevant public records and produces documented analysis of whether each contract’s predefined terms have been met. Kalshi operates the markets and retains sole responsibility for contract listings and final settlement decisions.
Separate from its work with Kalshi, AppliedXL offers real-time catalyst tracking, independent probability-of-success models, and five years of point-in-time clinical, regulatory, and company data through its SaaS platform and API.
Fundamental and systematic investment teams use the platform to track catalysts, evaluate drug programs, reconstruct what was publicly known at a specific date, and test investment models against historical outcomes. AppliedXL’s probability estimates are generated independently of Kalshi market prices, allowing teams to compare model-based forecasts with market-implied probabilities and subsequent outcomes.
AppliedXL offers a complimentary two-week Platform trial and systematic back testing. More here on the Kalshi partnership and AppliedXL.
AppliedXL Case Study – Giredestrant
AppliedXL’s clinical-trial forecasting model demonstrates how AI-driven analysis of public clinical data can help investors assess the likely outcome of drug-development programs before definitive results are announced.
In Hoffmann-La Roche’s Phase 3 trial for Giredestrant, AppliedXL’s model tracked the breast-cancer therapy through successive clinical-trial developments, continuously updating its probability assessment as new evidence emerged. Rather than relying solely on headline announcements, AppliedXL evaluated registry events and compared them with patterns from historically similar trials, weighting similarities across drug chemistry, target biology, indication and treatment modality.
The approach gave clients a transparent, point-in-time view of how the probability of success was changing and why. This was particularly valuable for Giredestrant, an investigational oral estrogen-receptor antagonist and degrader being evaluated in ER-positive, HER2-negative breast cancer. Subsequent clinical evidence showed a mixed picture: the Phase II acelERA trial did not achieve statistical significance on its primary progression-free-survival endpoint, although Giredestrant demonstrated treatment effects in several subgroups.
Giredestrant’s adjuvant breast cancer trial faced endpoint uncertainty through late 2023 before readout resolved the question, leaving the drug’s regulatory path as the sole open question. The following are AppliedXL’s forecasts for the drug’s major clinical trial and regulatory hurdles.
- Endpoint Success: 61% (Frozen at readout)
- Clinical Significance: 69% (Frozen at readout)
- Regulatory Approval: 91% (Live — still tracking)
The case illustrates AppliedXL’s potential to provide investors with an evidence-based framework for anticipating clinical outcomes rather than simply reacting to them after the fact. Click here to review a few other case studies of using AppliedXL’s platform to monitor and forecast the likelihood of various drugs’ success in being approved by the FDA.
Our Take
The Kalshi / AppliedXL biotech pilot addresses one of the more persistent frustrations in pharmaceutical investing: the absence of a transparent, liquid mechanism for pricing binary event risk before a trial reads out or a regulator acts.
Options markets on biotech names do this imperfectly, since implied volatility prices uncertainty in aggregate rather than isolating the specific outcome. A prediction market that resolves against a named FDA document prices the specific event directly, which is a cleaner signal for portfolio construction.
The safeguards Kalshi and AppliedXL built into the pilot are the element that deserves the most scrutiny. Employment verification and insider-trading prohibitions are the right architecture, but enforcement against a distributed participant base is genuinely difficult.
The biotech sector has a well-documented history of selective disclosure and information leakage ahead of regulatory decisions, and any market where informed participants can trade against uninformed ones will face that pressure continuously. Threading that needle is not a theoretical challenge; it is an operational one that will determine whether the pilot scales or stalls.
For buy-side analysts covering healthcare and biotech, the more immediate question is whether these markets generate information before it reaches other channels. If Kalshi biotech contracts begin to move meaningfully ahead of FDA decisions or trial announcements, they become an alternative data feed worth monitoring regardless of whether a fund trades them directly. That informational role is where prediction markets have historically delivered the most value to institutional investors.
The joint whitepaper signals that Kalshi and AppliedXL are building toward a permanent product category rather than a one-cycle experiment. It will be interesting to see how contract volume and accuracy develop across the first several FDA decisions in the pilot, since those numbers will shape whether larger healthcare-focused funds engage as participants or simply track the markets as an additional data source.
The partnership between AppliedXL and Kalshi is strategically important to AppliedXL because it gives the AI firm a high-profile commercial application for its ability to monitor, structure, and interpret fragmented public information. Under the pilot, AppliedXL provides resolution analysis for Kalshi contracts tied to clinical-trial outcomes and FDA decisions, using source-linked evidence from public records such as ClinicalTrials.gov and FDA documents.
In addition, the relationship potentially validates AppliedXL’s technology beyond traditional investment-research applications by making its data infrastructure part of an emerging prediction-market ecosystem. It also positions the company at the intersection of alternative data, AI-driven information extraction, forecasting, and event-based markets. The partnership could create a scalable model in which AppliedXL becomes a trusted infrastructure provider for resolving complex real-world events, potentially extending beyond biopharma into other domains.
More broadly, the relationship increases AppliedXL’s visibility among institutional investors and demonstrates how its technology can transform fragmented public information into structured, auditable intelligence that supports both forecasting and market-based decision-making.
For more news about alternative data, investment research, and investment related FinTech, click here to sign up for our free ResearchWatch Weekly newsletter, or click here to subscribe to our proprietary ResearchWatch news and commentary service.